-
公开(公告)号：EP3954387A1
公开(公告)日：2022-02-16
申请号：EP20787629.3
申请日：2020-04-08
Applicant: Tohoku University , Junsei Educational Institution , Fuso Pharmaceutical Industries, Ltd.
Inventor： KIKUCHI, Haruhisa , OSHIMA, Yoshiteru , HATTORI, Toshio , YAMADA, Osamu , ZHANG, Jing , KIDA, Shinya , MURASE, Shinya
IPC: A61K39/39 , A61P31/00 , A61P31/06 , A61P31/14 , A61P31/18 , A61P31/20 , A61P31/22 , A61P35/00 , A61P35/02 , A61P37/04 , A61P43/00 , C07D211/60 , A61K31/445
Abstract: The present invention provides a compound of formula (I):
or a pharmaceutically acceptable salt thereof, wherein R 1 , R 2 , m and n are as defined in the specification, with an inhibitory effect of PD-L1 expression and an inhibitory effect of reduced production of IL-2 and a medicament useful for the treatment of a disease associated with the reduced immune function caused by the formation of PD-1/PD-L1 binding.-
2.发明公开
公开(公告)号：EP3919052A1
公开(公告)日：2021-12-08
申请号：EP20739000.6
申请日：2020-01-09
Applicant: Fuso Pharmaceutical Industries, Ltd.
Inventor： SHINTO, Saki , ISHIDA, Minato , YAMAMOTO, Keiichi , YAMADA, Ken-ichi
IPC: A61K31/137 , A61K31/403 , A61K31/407 , A61K31/47 , A61P27/02 , A61K9/06 , A61K9/08 , A61K9/20
Abstract: The present invention provides a pharmaceutical composition for intraocular administration or oral administration, for preventing or treating a retinal disease (such as age-related macular degeneration), or suppressing a progression of the disease in a subject in need of treatment, the composition comprising an effective amount of one or more compounds selected from the following group, and a pharmaceutically acceptable carrier; and a method threfor, a group consisting of apomorphine, eseroline, ethoxyquin, methyldopa, olanzapine and indapamide.
-
3.发明公开
公开(公告)号：EP3617229A1
公开(公告)日：2020-03-04
申请号：EP18791391.8
申请日：2018-04-27
Applicant: Yamada, Ken-Ichi , Fuso Pharmaceutical Industries, Ltd.
Inventor： YAMADA, Ken-ichi , IDE, Tomomi , ISHIDA, Yuma , ICHIEN, Go , YAMAMOTO, Keiichi
IPC: C07K16/18 , C07D413/12 , G01N21/78 , G01N33/53
Abstract: The present invention provides a detection reagent for comprehensively detecting an oxidized state and a glycated state of a low-density lipoprotein. More specifically, according to the present invention, while an oxidized low-density lipoprotein and a glycated low-density lipoprotein are detected with a fluolophore-labelled antibody, a lipid radical is detected with a fluorescent nitroxide 2,2,6-trimethyl-4-(4-nitrobenzo[1,2,5]oxadiazol-7-ylamino)-6-pentylpiperadine-1-ox yl (NBD-Pen).
-
公开(公告)号：EP3480184A1
公开(公告)日：2019-05-08
申请号：EP18206567.2
申请日：2014-11-12
Applicant: Fuso Pharmaceutical Industries, Ltd.
Inventor： SHIMAMURA, Hideo , MURAKAMI, Tadataka , KURATA, Yasunori , KATO, Ayaka
Abstract: A novel highly stable sodium diacetate crystal, in which the volatilization of acetic acid can be suppressed for a long period. More specifically, a sodium diacetate crystal having a median diameter in the range of 300 to 3000 µm.
-
5.发明授权
公开(公告)号：EP2192184B8
公开(公告)日：2017-11-08
申请号：EP08828171.2
申请日：2008-08-29
IPC: C12N15/09 , C07K14/205 , C07K16/12 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12P21/02 , C12Q1/68 , G01N33/569
CPC classification number: C12Q1/689 , C07K16/1203 , C07K16/121 , C07K2317/76 , C12Q2600/158 , C12Q2600/16 , G01N33/56922 , G01N2333/205 , Y02A50/451
Abstract: An objective of the present invention is to provide the cytolethal distending toxin (CDT) of C . hyointestinalis and polynucleotides encoding it, and novel methods for detection of C . hyointestinalis using the cdt genes. The present inventors focused on the cytolethal distending toxin (CDT) of Campylobacter bacteria, and detected the cdt genes of a Campylobacter -like bacterium isolated from an enteritis patient in Thailand. The present inventors discovered a bacterial strain whose cdtB gene was amplified by common primers in C. jejuni , C. coli, and C . fetus, but not by multiplex PCR that can specifically detect the cdtA , cdtB , and cdtC genes of the three bacterial species. The bacterial strain was identified as C . hyointestinalis by 16S rRNA gene analysis. Furthermore, the entire nucleotide sequence of the cdt genes was determined by genome walking upstream and downstream of the cdtB gene.
-
Patent Agency Ranking6.发明授权MODEL ANIMAL FOR PREGNANCY-INDUCED HYPERTENSION SYNDROME, AND TREATMENT METHOD THEREFOR 有权妊娠高血压综合症模型动物及其治疗方法
公开(公告)号：EP2543729B1
公开(公告)日：2017-11-01
申请号：EP11750820.0
申请日：2011-03-04
Applicant: Okabe, Masaru , Ikawa, Masahito , Fuso Pharmaceutical Industries, Ltd.
Inventor： KIMURA, Tadashi , KUMASAWA, Keiichi , OKABE, Masaru , IKAWA, Masahito
CPC classification number: A01K67/0278 , A01K67/0271 , A01K67/0275 , A01K2207/12 , A01K2207/15 , A01K2217/052 , A01K2217/072 , A01K2227/105 , A01K2267/0375 , A01K2267/0393 , A61D19/04 , C12N9/12 , C12N9/1205 , C12N15/8509 , C12N15/86 , C12N15/873 , C12N2015/8527 , C12N2740/15043 , C12N2740/16043 , C12N2799/027
-
公开(公告)号：EP3112343A1
公开(公告)日：2017-01-04
申请号：EP15755910.5
申请日：2015-02-27
Applicant: Tohoku University , National University Corporation Gunma University , Fuso Pharmaceutical Industries, Ltd.
Inventor： KIKUCHI, Haruhisa , OSHIMA, Yoshiteru , HATTORI, Toshio , KUBOHARA, Yuzuru , YAMADA, Osamu , ZHANG, Jing , MATSUSHITA, Yoshihisa , KIDA, Shinya
IPC: C07C235/50 , A61K31/165 , A61K31/166 , A61K31/351 , A61K31/4045 , A61K31/437 , A61P1/16 , A61P9/10 , A61P11/00 , A61P13/04 , A61P19/02 , A61P19/10 , A61P25/00 , A61P29/00 , A61P35/00 , A61P43/00 , C07C233/36 , C07C233/62 , C07C233/78 , C07C235/48
CPC classification number: C07C235/50 , A61K31/165 , A61K31/166 , A61K31/167 , A61K31/351 , A61K31/381 , A61K31/397 , A61K31/40 , A61K31/4045 , A61K31/437 , A61K31/4409 , A61K31/445 , C07C233/36 , C07C233/62 , C07C233/78 , C07C235/48 , C07C235/60 , C07C237/22 , C07C237/34 , C07C237/42 , C07C2101/14 , C07C2601/14 , C07D205/04 , C07D207/16 , C07D209/14 , C07D211/60 , C07D213/81 , C07D309/08 , C07D333/38 , C07D471/04
Abstract: The present invention provides a useful medicament for the treatment and/or prophylaxis of a disease associated with the enhancement of OPN production including cancer, which comprises a compound of formula:
wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , m, n, p, X, and Y are as defined in the specification, or a pharmaceutically acceptable salt thereof.Abstract translation: 本发明提供了一种治疗和/或预防与包括癌症在内的OPN产生增强有关的疾病的有用药物，其包含下式的化合物：其中R 1，R 2，R 3，R 4，R 5， R 6，R 7，m，n，p，X和Y如说明书中所定义，或其药学上可接受的盐。
-
8.发明授权EXPRESSION VECTOR FOR MASS PRODUCTION OF FOREIGN GENE-DERIVED PROTEIN USING ANIMAL CELL AND USE THEREOF 有权表达载体蛋白的大规模生产利用动物外源基因的细胞及其用途
公开(公告)号：EP2258843B1
公开(公告)日：2016-11-16
申请号：EP09715053.6
申请日：2009-02-27
Applicant: National University Corporation Hokkaido University , FUSO PHARMACEUTICAL INDUSTRIES, LTD.
Inventor： SUZUKI, Yasuhiko , YAMAMOTO, Keiichi , TAHARA, Hiroshi , SUZUKI, Yusuke
CPC classification number: C12N15/85 , C12N9/1205 , C12N2830/50 , C12N2840/102 , C12Y207/01095
-
公开(公告)号：EP2383338B1
公开(公告)日：2016-10-19
申请号：EP11002042.7
申请日：2006-03-31
Inventor： Kase, Tetsuo , Kimura, Akio , Ueyama, Hiroshi , Nishihara, Mizuki , Kisaki, Hiroshi , Keshi, Hiroyuki
-
10.发明公开NOVEL SODIUM DIACETATE CRYSTAL AND SOLID DIALYSIS PREPARATION COMPRISING SAID CRYSTAL 有权脱氧尿嘧啶脱乙酰壳多糖在食品中DIALYSEPRÄPARATMIT DIESEM KRISTALL
公开(公告)号：EP3070075A1
公开(公告)日：2016-09-21
申请号：EP14861241.9
申请日：2014-11-12
Applicant: Fuso Pharmaceutical Industries, Ltd.
Inventor： SHIMAMURA, Hideo , MURAKAMI, Tadataka , KURATA, Yasunori , KATO, Ayaka
Abstract: A novel highly stable sodium diacetate crystal, in which the volatilization of acetic acid can be suppressed for a long period. More specifically, a sodium diacetate crystal having a median diameter in the range of 300 to 3000 µm.
Abstract translation: 一种新型高度稳定的二乙酸二乙酯晶体，其中可以长期抑制乙酸的挥发。 更具体地说，中值粒径为300〜3000μm的二乙酸二钠晶体。
-
-
-
-
-
-
-
-
-
Search Results
177
records
(took 0.032 seconds)
